A new AI-powered platform provides meal suggestions, ingredient substitutions, and meal planning guidance to help patients avoid their identified trigger foods.

Biomerica Inc has launched its inFoods IBS Trigger Food Navigator, an AI-powered digital companion tool designed to improve dietary compliance for patients with irritable bowel syndrome (IBS) following food sensitivity testing.

The Navigator builds on Biomerica’s existing inFoods IBS test, a laboratory-developed test that uses a finger-stick blood sample to identify specific food triggers responsible for IBS symptoms. The test typically identifies two to four trigger foods per patient, enabling targeted dietary modifications rather than broad elimination diets.

The new AI-backed tool provides meal suggestions, ingredient substitutions, and meal planning guidance to help patients avoid their identified trigger foods while maintaining dietary variety. The system was developed in collaboration with dietitians from the University of Michigan.

“Unlike broad elimination diets, inFoods IBS has the ability to identify select and specific IBS trigger foods, which makes compliance more achievable,” says Zack Irani, CEO of Biomerica, in a release. “The new AI-backed Trigger Food Navigator takes this one step further by guiding patients through everyday food choices and offering easy substitutions.”

Clinical Evidence and Laboratory Testing

The inFoods IBS test is performed as a CLIA-certified laboratory-developed test for high-complexity testing. A multicenter, double-blind clinical study published in Gastroenterology demonstrated statistically significant outcomes:

  • 59.6% of patients in the treatment group (who eliminated identified trigger foods) achieved the FDA’s endpoint for abdominal pain reduction, compared to 42.2% in the control group.
  • Among IBS-C patients, 67.1% of patients in the treatment group vs. 35.8% in the control group.
  • Among IBS-M patients, 66.0% of patients in the treatment group vs. 29.5% in the control group.

The study was conducted at Cleveland Clinic, Mayo Clinic, University of Michigan, and Beth Israel Deaconess Medical Center. Results showed the test was particularly effective for IBS-M patients, a mixed-symptom subgroup that has been historically underserved by existing treatments.

The test measures patient immune responses to specific foods through blood analysis, enabling physicians to recommend targeted dietary changes based on individual immunological profiles rather than generalized dietary restrictions.

Market Access and Integration

The Navigator is included at no additional cost for patients who have purchased the inFoods IBS test, with access activated through a purchase confirmation code. The tool can be ordered through participating healthcare providers or online for new patients.

Healthcare providers can access demonstration materials to understand how the Navigator integrates with existing treatment protocols. The system aims to strengthen patient-provider relationships by improving treatment adherence and symptom management outcomes. The launch represents Biomerica’s expansion into digital health tools that support laboratory-based diagnostic testing.

ID 241952195 © Skypixel | Dreamstime.com